Sodium–Glucose Cotransporter 2 Inhibitors for Transthyretin Amyloid Cardiomyopathy: Analyses of Short-Term Efficacy and Safety

Abstract

Sodium-glucose cotransporter 2 inhibitors were well tolerated by most patients with ATTR-CM and appeared to improve volume status and combat diuretic resistance. Randomized studies are needed to confirm these findings.